About: XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.76 (-5.63%)
XTLB NASDAQ XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd ADR share price
Atividade de preço de XTLB
Último preço
$ 1,760
Variação (24h)
-0,11 USD (5,63%)
Volume
7.06K
Volume (média 4 sem.)
-
Abertura
$ 1,90
Variação do dia
$ 1,76 - $ 1,90
Fechamento anterior
$ 1,87
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
XTLB price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals